Stockreport

The promising results of a phase II clinical study for Akeso's Cadonilimab (PD-1/CTLA-4) combined standard treatment for first-line treatment of R/M cervical cancer has been published in C...

LENOVO GROUP LTD S/ADR  (LNVGY) 
NASDAQ:AMEX Investor Relations: www3.lenovo.com/us/en/lenovo/investor_relations
PDF HONG KONG, Feb. 28, 2024 /PRNewswire/ -- Akeso (9926.HK) announced that the results of a phase II clinical trial for PD-1/CTLA-4 bispecific antibody(cadonilimab)combined [Read more]